Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results

Introduction: Subjective cognitive decline (SCD) has been proposed as a potential preclinical stage of Alzheimer's disease (AD). Nevertheless, the genetic and biomarker profiles of SCD individuals remain mostly unexplored. Methods: We evaluated apolipoprotein E (APOE) ε4's effect in the ri...

Full description

Bibliographic Details
Authors: Moreno Grau, Sonia, Rodríguez Gómez, Octavio, Sanabria, Ángela, Pérez Cordón, Alba, Sánchez Ruiz, Domingo, Abdelnour, Carla, Valero, Sergi, Hernández Alvarez, María Isabel, Rosende-Roca, Maitée, Mauleón, Ana, Vargas, Liliana, Lafuente, Asunción, Gil, Silvia, Santos Santos, Miguel A., Alegret, Montserrat, Espinosa, Ana, Ortega, Gemma, Guitart, Marina, Gailhajanet, Anna, Rojas, Itziar de, Sotolongo-Grau, Oscar, Ruiz, Susana, Aguilera, Nuria, Papasey, Judith, Martín, Elvira, Peleja, Esther, Lomeña Caballero, Francisco Juan, Campos, Francisco, Vivas, Assumpta, Gómez Chiari, Marta, Tejero, Miguel Ángel, Giménez, Joan, Serrano Ríos, Manuel, Orellana, Adelina, Tárraga, Lluís, Ruiz, Agustín, Boada, Mercè, Alzheimer's Disease Neuroimaging Initiative, FACEHBI study group
Format: article
Status:Published version
Publication Date:2017
Country:España
Institution:Universidad de Barcelona
Repository:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/176163
Online Access:https://hdl.handle.net/2445/176163
Access Level:Open access
Keyword:Malaltia d'Alzheimer
Malalties del sistema nerviós
Alzheimer's disease
Nervous system Diseases
Description
Summary:Introduction: Subjective cognitive decline (SCD) has been proposed as a potential preclinical stage of Alzheimer's disease (AD). Nevertheless, the genetic and biomarker profiles of SCD individuals remain mostly unexplored. Methods: We evaluated apolipoprotein E (APOE) ε4's effect in the risk of presenting SCD, using the Fundacio ACE Healthy Brain Initiative (FACEHBI) SCD cohort and Spanish controls, and performed a meta-analysis addressing the same question. We assessed the relationship between APOE dosage and brain amyloid burden in the FACEHBI SCD and Alzheimer's Disease Neuroimaging Initiative cohorts. Results: Analysis of the FACEHBI cohort and the meta-analysis demonstrated SCD individuals presented higher allelic frequencies of APOE ε4 with respect to controls. APOE dosage explained 9% (FACEHBI cohort) and 11% (FACEHBI and Alzheimer's Disease Neuroimaging Initiative cohorts) of the variance of cerebral amyloid levels. Discussion: The FACEHBI sample presents APOE ε4 enrichment, suggesting that a pool of AD patients is nested in our sample. Cerebral amyloid levels are partially explained by the APOE allele dosage, suggesting that other genetic or epigenetic factors are involved in this AD endophenotype.

Similar Items